Neuroprotective and neurotrophic curcuminoids to treat stroke: A translational perspective

Expert Opinion on Investigational Drugs

Volumn 20, Issue 1, 2011, Pages 13-22

  Lapchak, Paul A ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

acute ischemic stroke; behavior; CNB 001; curcumin; embolism; mortality; neuroprotection; polyphenol; subarachnoid hemorrhage; toxicity; translational science

Indexed keywords

1,11 DI (4 METHOXYPHENYL) 1,3,8,10 UNDECA TETRAEN 5,7 DIONE; 2 [5 (4 HYDROXY 3 METHOXYSTYRYL) 1 PHENYL 1H PYRAZOYL 3 YL] 2 METHOXYPHENOL; 4,4' ISOPROPYLIDENEDIPHENOL; ALTEPLASE; CNB 001; CURCUMIN; DEMETHOXYCURCUMIN; DIDEMETHOXYCURCUMIN; DISUFENTON SODIUM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NORPHENAZONE; PROSTAGLANDIN SYNTHASE INHIBITOR; TETRAHYDROCURCUMIN; TISSUE PLASMINOGEN ACTIVATOR; TURMERONE; UNCLASSIFIED DRUG;

BRAIN HEMORRHAGE; BRAIN ISCHEMIA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG STRUCTURE; EPIDEMIOLOGICAL DATA; HUMAN; IC 50; INCIDENCE; INDIA; NEUROPROTECTION; NONHUMAN; NORTH AMERICA; PREVALENCE; REVIEW; STROKE;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN ISCHEMIA; CURCUMIN; DRUG DELIVERY SYSTEMS; HUMANS; INDIA; NEUROPROTECTIVE AGENTS; NORTH AMERICA; PERMEABILITY; PYRAZOLES; STROKE;

EID: 78650269039     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2011.542410     Document Type: Review

References (88)

1. Kuroda M, Mimaki Y, Nishiyama T, et al. Hypoglycemic effects of turmeric (Curcuma longa L. rhizomes) on genetically diabetic KK-Ay mice. Biol Pharm Bull 2005;28:937-9
2. Nishiyama T, Mae T, Kishida H, et al. Curcuminoids and sesquiterpenoids in turmeric (Curcuma longa L.) suppress an increase in blood glucose level in type 2 diabetic KK-Ay mice. J Agric Food Chem 2005;53:959-63
3. Yue GG, Chan BC, Hon PM, et al. Immunostimulatory activities of polysaccharide extract isolated from Curcuma longa. Int J Biol Macromol 2010;47:342-7
4. Yue GG, Chan BC, Hon PM, et al. Evaluation of in vitro anti-proliferative and immunomodulatory activities of compounds isolated from Curcuma longa. Food Chem Toxicol 2010;48:2011-20
5. Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev 2009;14:141-53
6. Petty GW, Brown RD Jr, Whisnant JP, et al. Ischemic stroke subtypes: a population-based study of functional outcome, survival, and recurrence. Stroke 2000;31:1062-8
7. Petty GW, Brown RD Jr, Whisnant JP, et al. Ischemic stroke subtypes: a population-based study of incidence and risk factors. Stroke 1999;30:2513-16
8. Lapchak PA. Hemorrhagic transformation following ischemic stroke: significance, causes, and relationship to therapy and treatment. Curr Neurol Neurosci Rep 2002;2:38-43
9. Lapchak PA, Araujo DM. Advances in hemorrhagic stroke therapy: conventional and novel approaches. Expert Opin Emerg Drugs 2007;12:389-406
10. Tonk M, Haan J. A review of genetic causes of ischemic and hemorrhagic stroke. J Neurol Sci 2007;257:273-9
11. Das SK, Banerjee TK. Stroke: Indian scenario. Circulation 2008;118:2719-24
12. Banerjee TK, Das SK. Epidemiology of stroke in India. Neurol Asia 2006;11:1-4
13. Kaul S. Stroke in India: are we different from the world? Pak J Neurol Sci 2007;2:158-64
14. Sethi PK. Stroke - incidence in India and management of ischaemic stroke. Neurosci Today 2002;VI:139-144
15. Banerjee I, Gupta V, Ahmed T, et al. Inflammatory system gene polymorphism and the risk of stroke: a case-control study in an Indian population. Brain Res Bull 2008;75:158-65
16. Das SK, Banerjee TK, Biswas A, et al. A prospective community-based study of stroke in Kolkata, India. Stroke 2007;38:906-10
17. Banerjee I, Gupta V, Ganesh S. Association of gene polymorphism with genetic susceptibility to stroke in Asian populations: a meta-analysis. J Hum Genet 2007;52:205-19
18. Lapchak PA. Development of thrombolytic therapy for stroke: a perspective. Expert Opin Investig Drugs 2002;11:1623-32
19. Sinha R, Anderson DE, McDonald SS, Greenwald P. Cancer risk and diet in India. J Postgrad Med 2003;49:222-8
20. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics- 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119:480-6
21. Ovbiagele B. Potential role of curcumin in stroke prevention. Expert Rev Neurother 2008;8:1175-6
22. Gogia A, Agarwal PK. Metabolic syndrome. Indian J Med Sci 2006;60:72-81
23. Prabhakaran D, Shah P, Chaturvedi V, et al. Cardiovascular risk factor prevalence among men in a large industry of northern India. Natl Med J India 2005;18:59-65
24. Ingall T. Stroke - incidence, mortality, morbidity and risk. J Insur Med 2004;36:143-52
25. Sharma M, Ansari MT, Abou-Setta AM, et al. Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia. Ann Intern Med 2009;151:622-30
26. Tenenbaum A, Fisman EZ, Motro M, Adler Y. Optimal management of combined dyslipidemia: what have we behind statins monotherapy? Adv Cardiol 2008;45:127-53
27. Amarenco P, Bogousslavsky J, Callahan A III, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-59
28. Montaner J. Treatment with statins in the acute phase of ischemic stroke. Expert Rev Neurother 2005;5:211-21
29. Kramer AH, Gurka MJ, Nathan B, et al. Statin use was not associated with less vasospasm or improved outcome after subarachnoid hemorrhage. Neurosurgery 2008;62:422-427; discussion 427-430
30. Meier N, Nedeltchev K, Brekenfeld C, et al. Prior statin use, intracranial hemorrhage, and outcome after intra-arterial thrombolysis for acute ischemic stroke. Stroke 2009;40:1729-37
31. Naval NS, Abdelhak TA, Zeballos P, et al. Prior statin use reduces mortality in intracerebral hemorrhage. Neurocrit Care 2008;8:6-12
32. Uyttenboogaart M, Koch MW, Koopman K, et al. Lipid profile, statin use, and outcome after intravenous thrombolysis for acute ischaemic stroke. J Neurol 2008;255:875-80
33. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999;22:391-7
34. Lapchak PA, Araujo DM. Advances in ischemic stroke treatment: neuroprotective and combination therapies. Expert Opin Emerg Drugs 2007;12:97-112
35. Moskowitz MA, Lo EH, Iadecola C. The science of stroke: mechanisms in search of treatments. Neuron 2010;67:181-98
36. Lapchak PA. Translational stroke research using a rabbit embolic stroke model: a correlative analysis hypothesis for novel therapy development. Transl Stroke Res 2010;1:96-107
37. Jain SK, Rains J, Croad J, et al. Curcumin supplementation lowers TNF-alpha, IL-6, IL-8, and MCP-1 secretion in high glucose-treated cultured monocytes and blood levels of TNF-alpha, IL-6, MCP-1, glucose, and glycosylated hemoglobin in diabetic rats. Antioxid Redox Signal 2009;11:241-9
38. Li Y, Wang P. Neuroprotective effects of curcumin. Zhongguo Zhong Yao Za Zhi 2009;34:3173-5
39. Lapchak PA. A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy? Expert Opin Pharmacother 2010;11:1753-63
40. Ginsberg MD. Current status of neuroprotection for cerebral ischemia: synoptic overview. Stroke 2009;40(3 Suppl):S111-14
41. Liu Y, Dargusch R, Maher P, Schubert D. A broadly neuroprotective derivative of curcumin. J Neurochem 2008;105:1336-45
42. Maher P, Akaishi T, Schubert D, Abe K. A pyrazole derivative of curcumin enhances memory. Neurobiol Aging 2008;31:706-9
43. Lapchak PA, KcKim JM. CeeTox™ analysis of CNB-001 a novel curcumin-based neurotrophic/neuroprotective lead compound to treat stroke: comparison with NXY-059 and Radicut. Transl Stroke Res 2011;2(1) DOI: 10.1007/s12975-010-0034-4
44. Lapchak PA, Maher P, Schubert D, Zivin JA. Baicalein, an antioxidant 12/15-lipoxygenase inhibitor improves clinical rating scores following multiple infarct embolic strokes. Neuroscience 2007;150:585-91
45. Abe K, Takayanagi M, Saito H. Effects of recombinant human basic FGF and its modified protein CS23 on survival of primary cultured neurons from various regions of fetal rat brain. Jpn J Pharmacol 1990;53:221-7
46. Handler N, Jaeger W, Puschacher H, et al. Synthesis of novel curcumin analogues and their evaluation as selective cyclooxygenase-1 (COX-1) inhibitors. Chem Pharm Bull (Tokyo) 2007;55:64-71
47. Lapchak PA, Araujo DM, Song D, Zivin JA. Neuroprotection by the selective cyclooxygenase-2 inhibitor SC-236 results in improvements in behavioral deficits induced by reversible spinal cord ischemia. Stroke 2001;32:1220-5
48. Chu K, Jeong SW, Jung KH, et al. Celecoxib induces functional recovery after intracerebral hemorrhage with reduction of brain edema and perihematomal cell death. J Cereb Blood Flow Metab 2004;24:926-33
49. Nogawa S, Forster C, Zhang F, et al. Interaction between inducible nitric oxide synthase and cyclooxygenase-2 after cerebral ischemia. Proc Natl Acad Sci USA 1998;95:10966-71
50. Lin H, Lin TN, Cheung WM, et al. Cyclooxygenase-1 and bicistronic cyclooxygenase-1/prostacyclin synthase gene transfer protect against ischemic cerebral infarction. Circulation 2002;105:1962-9
51. Ghoneim AI, Abdel-Naim AB, Khalifa AE, El-Denshary ES. Protective effects of curcumin against ischaemia/reperfusion insult in rat forebrain. Pharmacol Res 2002;46:273-9
52. Thiyagarajan M, Sharma SS. Neuroprotective effect of curcumin in middle cerebral artery occlusion induced focal cerebral ischemia in rats. Life Sci 2004;74:969-85
53. Rathore P, Dohare P, Varma S, et al. Curcuma oil: reduces early accumulation of oxidative product and is anti-apoptogenic in transient focal ischemia in rat brain. Neurochem Res 2008;33:1672-82
54. Shukla PK, Khanna VK, Ali MM, et al. Anti-ischemic effect of curcumin in rat brain. Neurochem Res 2008;33:1036-43
55. Zhao J, Yu S, Zheng W, et al. Curcumin improves outcomes and attenuates focal cerebral ischemic injury via antiapoptotic mechanisms in rats. Neurochem Res 2010;35:374-9
56. Yang C, Zhang X, Fan H, Liu Y. Curcumin upregulates transcription factor Nrf2, HO-1 expression and protects rat brains against focal ischemia. Brain Res 2009;1282:133-41
57. Ferguson KN, Kidwell CS, Starkman S, Saver JL. Hyperacute treatment initiation in neuroprotective agent stroke trials. J Stroke Cerebrovasc Dis 2004;13:109-12
58. Dohare P, Garg P, Jain V, et al. Dose dependence and therapeutic window for the neuroprotective effects of curcumin in thromboembolic model of rat. Behav Brain Res 2008;193:289-97
59. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-29
60. Lyden P, Lu M, Jackson C, et al. Underlying structure of the National Institutes of Health Stroke Scale: results of a factor analysis. NINDS tPA Stroke Trial Investigators. Stroke 1999;30:2347-54
61. Cole GM, Teter B, Frautschy SA. Neuroprotective effects of curcumin. Adv Exp Med Biol 2007;595:197-212
62. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm 2007;4:807-18
63. Lapchak PA, Schubert DR, Maher PA. Delayed treatment with a novel neurotrophic compound reduces behavioral deficits in rabbit ischemic stroke. J Neurochem 2011;116(1):122-31
64. Lo EH, Rosenberg GA. The neurovascular unit in health and disease: introduction. Stroke 2009;40(3 Suppl):S2-3
65. Michel P, Bogousslavsky J. Penumbra is brain: no excuse not to perfuse. Ann Neurol 2005;58:661-3
66. Fisher M. The ischemic penumbra: identification, evolution and treatment concepts. Cerebrovasc Dis 2004;17:1-6
67. Muir KW. Heterogeneity of stroke pathophysiology and neuroprotective clinical trial design. Stroke 2002;33:1545-50
68. Lapchak PA, Schubert D, Maher P. The curcumin-based derivative CNB-001 attenuates ischemia-induced cell death in vitro and reduces embolism-induced clinical deficits in vivo in a rabbit stroke model: neuroprotection is mediated via an Erk-ORP150 pathway. Stroke 2010;41(e276):P85
69. Bath PM, Gray LJ, Bath AJ, et al. Effects of NXY-059 in experimental stroke: an individual animal meta-analysis. Br J Pharmacol 2009;157:1157-71
70. Mehta SL, Manhas N, Raghubir R. Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res Rev 2007;54:34-66
71. Zhao H, Sapolsky RM, Steinberg GK. Phosphoinositide-3-kinase/akt survival signal pathways are implicated in neuronal survival after stroke. Mol Neurobiol 2006;34:249-70
72. Liu C, Wu J, Xu K, et al. Neuroprotection by baicalein in ischemic brain injury involves PTEN/AKT pathway. J Neurochem 2010;112:1500-12
73. Liu Y, Dargusch R, Maher P, Schubert D. A broadly neuroprotective derivative of curcumin. J Neurochem 2008;105:1336-45
74. Rossler OG, Giehl KM, Thiel G. Neuroprotection of immortalized hippocampal neurones by brain-derived neurotrophic factor and Raf-1 protein kinase: role of extracellular signal-regulated protein kinase and phosphatidylinositol 3-kinase. J Neurochem 2004;88:1240-52
75. Schratt GM, Nigh EA, Chen WG, et al. BDNF regulates the translation of a select group of mRNAs by a mammalian target of rapamycin-phosphatidylinositol 3-kinase-dependent pathway during neuronal development. J Neurosci 2004;24:7366-77
76. Tamatani M, Matsuyama T, Yamaguchi A, et al. ORP150 protects against hypoxia/ischemia-induced neuronal death. Nat Med 2001;7:317-23
77. Wang R, Li YH, Xu Y, et al. Curcumin produces neuroprotective effects via activating brain-derived neurotrophic factor/TrkB-dependent MAPK and PI-3K cascades in rodent cortical neurons. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:147-53
78. NINDS. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-7
79. Lapchak PA. Taking a light approach to treating acute ischemic stroke patients: transcranial near-infrared laser therapy. Transl Sci 2010;42:576-86
80. Lapchak PA, Chapman DF, Zivin JA. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke 2000;31:3034-40
81. Rosenberg GA. Matrix metalloproteinases in brain injury. J Neurotrauma 1995;12:833-42
82. Chen B, Friedman B, Cheng Q, et al. Severe blood-brain barrier disruption and surrounding tissue injury. Stroke 2009;40:e666-74
83. Taheri S, Candelario-Jalil E, Estrada EY, Rosenberg GA. Spatiotemporal correlations between blood-brain barrier permeability and apparent diffusion coefficient in a rat model of ischemic stroke. PLoS One 2009;4(8):e6597
84. Jiang J, Wang W, Sun YJ, et al. Neuroprotective effect of curcumin on focal cerebral ischemic rats by preventing blood-brain barrier damage. Eur J Pharmacol 2007;561:54-62
85. Yazawa K, Kihara T, Shen H, et al. Distinct mechanisms underlie distinct polyphenol-induced neuroprotection. FEBS Lett 2006;580:6623-8
86. Wakade C, King MD, Laird MD, et al. Curcumin attenuates vascular inflammation and cerebral vasospasm after subarachnoid hemorrhage in mice. Antioxid Redox Signal 2009;11(1):35-45
87. Wang R, Li YB, Li YH, et al. Curcumin protects against glutamate excitotoxicity in rat cerebral cortical neurons by increasing brain-derived neurotrophic factor level and activating TrkB. Brain Res 2008;1210:84-91
88. Khanna S, Park HA, Sen CK, et al. Neuroprotective and antiinflammatory properties of a novel demethylated curcuminoid. Antioxid Redox Signal 2009;11:449-68